These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 15196735)

  • 1. A treatment planning study evaluating a 'simultaneous integrated boost' technique for accelerated radiotherapy of stage III non-small cell lung cancer.
    Dirkx ML; van Sörnsen De Koste JR; Senan S
    Lung Cancer; 2004 Jul; 45(1):57-65. PubMed ID: 15196735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraindividual comparison of conventional three-dimensional radiotherapy and intensity modulated radiotherapy in the therapy of locally advanced non-small cell lung cancer a planning study.
    Marnitz S; Stuschke M; Bohsung J; Moys A; Reng I; Wurm R; Budach V
    Strahlenther Onkol; 2002 Nov; 178(11):651-8. PubMed ID: 12426677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer.
    Murshed H; Liu HH; Liao Z; Barker JL; Wang X; Tucker SL; Chandra A; Guerrero T; Stevens C; Chang JY; Jeter M; Cox JD; Komaki R; Mohan R
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1258-67. PubMed ID: 15001271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
    Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer.
    Liu HH; Wang X; Dong L; Wu Q; Liao Z; Stevens CW; Guerrero TM; Komaki R; Cox JD; Mohan R
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1268-79. PubMed ID: 15001272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy.
    Thirion P; Holmberg O; Collins CD; O'Shea C; Moriarty M; Pomeroy M; O'Sullivan C; Buckney S; Armstrong J
    Radiother Oncol; 2004 May; 71(2):163-6. PubMed ID: 15110449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer.
    Li XA; Wang JZ; Jursinic PA; Lawton CA; Wang D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1251-7. PubMed ID: 15752907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study.
    Cho KH; Ahn SJ; Pyo HR; Kim KS; Kim YC; Moon SH; Han JY; Kim HT; Koom WS; Lee JS
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1397-404. PubMed ID: 19117690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy.
    Onimaru R; Fujino M; Yamazaki K; Onodera Y; Taguchi H; Katoh N; Hommura F; Oizumi S; Nishimura M; Shirato H
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):374-81. PubMed ID: 18029106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of intensity-modulated radiation therapy as a boost treatment on the lung-dose distributions for non-small-cell lung cancer.
    Choi Y; Kim JK; Lee HS; Hur WJ; Chai GY; Kang KM
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):683-9. PubMed ID: 15927412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-dimensional conformal simultaneously integrated boost technique for breast-conserving radiotherapy.
    van der Laan HP; Dolsma WV; Maduro JH; Korevaar EW; Hollander M; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1018-23. PubMed ID: 17379440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial.
    van Baardwijk A; Bosmans G; Bentzen SM; Boersma L; Dekker A; Wanders R; Wouters BG; Lambin P; De Ruysscher D
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1103-10. PubMed ID: 18258382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-volume image-guided radiotherapy using hypofractionated, coplanar, and noncoplanar multiple fields for patients with inoperable Stage I nonsmall cell lung carcinomas.
    Fukumoto S; Shirato H; Shimzu S; Ogura S; Onimaru R; Kitamura K; Yamazaki K; Miyasaka K; Nishimura M; Dosaka-Akita H
    Cancer; 2002 Oct; 95(7):1546-53. PubMed ID: 12237924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma.
    Rosenzweig KE; Fox JL; Yorke E; Amols H; Jackson A; Rusch V; Kris MG; Ling CC; Leibel SA
    Cancer; 2005 May; 103(10):2118-27. PubMed ID: 15830346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic control probability in tumour subvolumes or how to guide tumour dose redistribution in non-small cell lung cancer (NSCLC): an exploratory clinical study.
    Petit SF; Aerts HJ; van Loon JG; Offermann C; Houben R; Winkens B; Ollers MC; Lambin P; De Ruysscher D; Dekker AL
    Radiother Oncol; 2009 Jun; 91(3):393-8. PubMed ID: 19328570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer.
    Schwarz M; Alber M; Lebesque JV; Mijnheer BJ; Damen EM
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):561-70. PubMed ID: 15890601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An accelerated radiotherapy scheme using a concomitant boost technique for the treatment of unresectable stage III non-small cell lung cancer.
    Izmirli M; Yaman F; Buyukpolat MY; Yoney A; Unsal M
    Jpn J Clin Oncol; 2005 May; 35(5):239-44. PubMed ID: 15886271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment plan comparison between helical tomotherapy and MLC-based IMRT using radiobiological measures.
    Mavroidis P; Ferreira BC; Shi C; Lind BK; Papanikolaou N
    Phys Med Biol; 2007 Jul; 52(13):3817-36. PubMed ID: 17664579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.